A pH-responsive high density lipoprotein-like nanoparticle of epothilone B

Biotechnology and Bioprocess Engineering

Volumn 20, Issue 2, 2015, Pages 249-258

  Lee, Ji Chun ^a   Kong, Byoung Jae ^a   Shin, Jae Yoon ^a   Shin, Jonghyeok ^a   Oh, Jung Su ^a   Cho, Jae Youl ^a   Yoon, Keejung ^a   Kim, Sung Gun ^b   Song, Young Ha ^c   Shin, Chol Su ^c   An, Heekyung ^d   Lee, Woo Jong ^d   Kweon, Dae Hyuk ^a  

^a Sungkyunkwan University   (South Korea)

^b Youngdong University   (South Korea)

^c Department of Biomedical Science Youngdong University ^*  (South Korea)

^d APTechnology Inc ^*  (South Korea)

Author keywords

apolipoprotein A I; high density lipoprotein; pH responsive; pothilone B; scavenger receptor class B type I

Indexed keywords

CELL CULTURE; CELL DEATH; CYTOLOGY; CYTOTOXICITY; LIPOPROTEINS; NANOPARTICLES;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-I (APOA-I); CLASS B; HIGH DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEINS; PH-RESPONSIVE; SCAVENGER RECEPTOR; STABILIZING AGENTS;

CELLS;

APOLIPOPROTEIN A1; EPOTHILONE B; HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CACO 2 CELL LINE; CANCER CELL; CELL VIABILITY; CODON; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; ENDOSOME; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIGHT SCATTERING; MCF 7 CELL LINE; MITOSIS INHIBITION; PH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84929472070     PISSN: 12268372     EISSN: 19763816     Source Type: Journal    
DOI: 10.1007/s12257-014-0368-y     Document Type: Article

References (32)

1. Mooberry, L. K., M. Nair, S. Paranjape, W. J. McConathy, and A. G. Lacko (2010) Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 18: 53–58.
2. Lacko, A. G., M. Nair, L. Prokai, and W. J. McConathy (2007) Prospects and challenges of the development of lipoproteinbased formulations for anti-cancer drugs. Expert. Opin. Drug. Deliv. 4: 665–675.
3. McConathy, W. J., M. P. Nair, S. Paranjape, L. Mooberry, and A. G. Lacko (2008) Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-Cancer Drugs 19: 183–188.
4. Lacko, A. G., M. Nair, S. Paranjape, S. Johnso, and W. J. McConathy (2002) High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 22: 2045–2049.
5. Shahzad, M. M., L. S. Mangala, H. D. Han, C. Lu, J. Bpttsford-Miller, M. Nishimura, E. M. Mora, J. W. Lee, R. L. Stone, C. V. Pecot, D. Thanapprapasr, J. W. Roh, P. Gaur, M. P. Nair, Y. Y. Park, Sabnis N, M. T. Deavers, J. S. Lee, L. M. Ellis, G. Lopez-Berestein, W. J. McConathy, L. Prokai, A. G. Lacko, and A. K. Sood (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 13: 309–319.
6. Kim, J. S., Y. Kang, K. H. Son, S. M. Choi, and K. Y. Kim (2011) Manufacturing and shelf stability of reconstituted high-density lipoprotein for infusion therapy. Biotechnol. Bioproc. Eng. 16: 785–792.
7. Ng, K. K., J. F. Lovell, and G. Zheng (2011) Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44: 1105–1113.
8. Ryan, R. O. (2010) Nanobiotechnology applications of reconstituted high density lipoprotein. J. Nanobiotechnol. 8: 28–37.
9. Connor, J., M. B. Yatvin, and L. Huang (1984) pH-sensitive liposomes: Acid-induced liposome fusion. Proc. Natl. Acad. Sci. USA. 81: 1715–1718.
10. Bae, Y., N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, and K. Kataoka (2005) Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16: 122–130.
11. Oh, K. T., D. Kim, H. H. You, Y. S. Ahn, and E. S. Lee (2009) pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. Int. J. Pharm. 376: 134–140.
12. Ganta, S., H. Devalapally, A. Shahiwala, and M. Amiji (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Rel. 126: 187–204.
13. Bae, Y., S. Fukushima, A. Harada, and K. Kataoka (2003) Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. Engl. 42: 4640–4643.
14. Paramonov, S. E., E. M. Bachelder, T. T. Beaudette, S. M. Standley, C. C. Lee, J. Dashe, and M. Fréchet (2008) Fully aciddegradable biocompatible polyacetal microparticles for drug delivery. Bioconjug. Chem. 19: 911–919.
15. Shin, J. Y., Y. Yang, P. Heo, J. C. Lee, B. Kong, J. Y. Cho, K. Yoon, C. S. Shin, J. H. Seo, S. G. Kim, and D. H. Kweon (2012) pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int. J. Nanomed. 7: 2805–2816.
16. Lee, F. Y., R. Borzilleri, C. R. Fairchild, S. H. Kim, B. H. Long, C. Reventos-Suarez, G. D. Vite, W. C. Rose, and R. A. Kramer (2001) BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7: 1429–1437.
17. Paik, D., E. Cocco, S. Bellone, F. Casagrande, M. Bellone, E. E. Siegel, C. E. Richter, P. E. Schwartz, T. J. Rutherford, and A. D. Santin (2010) Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol. Oncol. 119: 140–145.
18. Kowalski, R. J., P. Giannakakou, and E. Hamel (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J. Biol. Chem. 272: 2534–2541.
19. Giannakakou, P., R. Gussio, E. Nogales, K. H. Downing, D. Zaharevitz, B. Bollbuck, G. Poy, D. Sackett, K. C. Nicolaou, and T. Fojo (1999) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA. 97: 2904–2909.
20. Forli, S., F. Manetti, K. Altmann, and M. Botta (2010) Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilone. Chem. Med. Chem. 5: 35–40.
21. Sepp-Lorenzino, L., A. Balog, D. S. Su, D. Meng, N. Timaul, H. I. Scher, S. J. Danichegsky, and N. Rosen (1999) The microtubule-stabilizing agents epothilones A and B and their desoxyderivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis. 2: 41–52.
22. Fumoleau, P., B. Coudert, N. Isambert, and E. Ferrant (2007) Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol. 18: v9–v15.
23. Kim, A. D., K. A. Kang, M. J. Piao, K. C. Kim, J. Zheng, C. W. Yao, J. W. Cha, C. L. Hyun, S. J. Boo, N. H. Lee, S. Y. Na, and J. W. Hyu (2014) Dictyopteris undulata extract induces apoptosis in human colon cancer cells. Biotechnol. Bioproc. Eng. 19: 419–425.
24. Huang, R., R. A. Silva, W. G. Jerome, A. Kontush, M. J. Chapman, L. K. Curtiss, T. J. Hodges, and W. S. Davidson (2011) Apolipoprotein AI structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18: 416–422.
25. Gao, W., J. M. Chan, and O. C. Farokhzad (2010) pH-responsive nanoparticles for drug delivery. Mol. Pharma. 7: 1913–1920.
26. Shen, Y., H. Tang, M. Radosz, E. Van Kirk, and W. J. Murdoch (2008) pH-responsive nanoparticles for cancer drug delivery. Methods Mol. Biol. 437: 183–216.
27. Sparks, D. L., S. Lund-Katz, and M. C. Phillips (1992) The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. J. Biol. Chem. 267: 25839–25847.
28. Holmes, F. A., R. S. Walters, R. L. Theriault, A. D. Forman, L. K. Newton, M. N. Raber, A. U. Buzdar, D. K. Frye, and G. N. Hortobagyi (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83: 1797–1805.
29. Wahl, A. F., K. L. Donaldson, C. Fairchild, F. Y. Lee, S. A. Foster, G. W. Demers, and D. A. Galloway (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2: 72–79.
30. Yu, D., T. Jing, B. Liu, J. Yao, M. Tan, T. J. McDonnell, and M. C. Hung (1998) Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell. 2: 581–591.
31. Sievers, E. L. and P. D. Senter (2013) Antibody-drug conjugates in cancer therapy. Annu Rev. Med. 64: 15–29.
32. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13: 235–244.